Search Results - "Dees, E"

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study by Nanda, Rita, Chow, Laura Q M, Dees, E Claire, Berger, Raanan, Gupta, Shilpa, Geva, Ravit, Pusztai, Lajos, Pathiraja, Kumudu, Aktan, Gursel, Cheng, Jonathan D, Karantza, Vassiliki, Buisseret, Laurence

“…Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in…”
Get full text

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study by Melichar, Bohuslav, Prof, Adenis, Antoine, Prof, Lockhart, A Craig, MD, Bennouna, Jaafar, Prof, Dees, E Claire, Prof, Kayaleh, Omar, MD, Obermannova, Radka, MD, DeMichele, Angela, MD, Zatloukal, Petr, Prof, Zhang, Bin, DSc, Ullmann, Claudio Dansky, MD, Schusterbauer, Claudia, MD

“…Summary Background Alisertib is an investigational, oral, selective inhibitor of aurora kinase A. We aimed to investigate the safety and activity of…”
Get full text

Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer by File, Danielle M., Pascual, Tomas, Deal, Allison M., Wheless, Amy, Perou, Charles M., Claire Dees, E., Carey, Lisa A.

“…Purpose This study evaluated whether patients with de novo metastatic breast cancer (MBC) have superior outcomes compared to those with recurrent MBC in a…”
Get full text

Improved Neutron Lifetime Measurement with UCN τ by Gonzalez, F. M., Fries, E. M., Cude-Woods, C., Bailey, T., Blatnik, M., Broussard, L. J., Callahan, N. B., Choi, J. H., Clayton, S. M., Currie, S. A., Dawid, M., Dees, E. B., Filippone, B. W., Fox, W., Geltenbort, P., George, E., Hayen, L., Hickerson, K. P., Hoffbauer, M. A., Hoffman, K., Holley, A. T., Ito, T. M., Komives, A., Liu, C.-Y., Makela, M., Morris, C. L., Musedinovic, R., O’Shaughnessy, C., Pattie, R. W., Ramsey, J., Salvat, D. J., Saunders, A., Sharapov, E. I., Slutsky, S., Su, V., Sun, X., Swank, C., Tang, Z., Uhrich, W., Vanderwerp, J., Walstrom, P., Wang, Z., Wei, W., Young, A. R.

“…We report an improved measurement of the free neutron lifetime τn using the UCN τ apparatus at the Los Alamos Neutron Science Center. We count a total of…”
Get full text

Nanoparticle-Delivered Chemotherapy: Old Drugs in New Packages by Lee, Michael S, Dees, E Claire, Wang, Andrew Z

“…Cytotoxic chemotherapies have a narrow therapeutic window, with high peaks and troughs of plasma concentration. Novel nanoparticle formulations of cytotoxic…”
Get more information

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors by Soliman, Hatem H, Jackson, Erica, Neuger, Tony, Dees, E Claire, Harvey, R Donald, Han, Hyo, Ismail-Khan, Roohi, Minton, Susan, Vahanian, Nicholas N, Link, Charles, Sullivan, Daniel M, Antonia, Scott

“…Indoleamine 2,3-dioxygenase (IDO) is an enzyme that tumors use to create a state of immunosuppression. Indoximod is an IDO pathway inhibitor. Preclinical…”
Get full text

Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors by Infante, Jeffrey R, Dees, E Claire, Olszanski, Anthony J, Dhuria, Shyeilla V, Sen, Suman, Cameron, Scott, Cohen, Roger B

“…LCL161 antagonizes the function of inhibitor of apoptosis proteins (IAPs), thereby promoting cancer cell death. This first-in-human dose-escalation study…”
Get full text

The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes by CAREY, Lisa A, DEES, E. Claire, SAWYER, Lynda, GATTI, Lisa, MOORE, Dominic T, COLLICHIO, Frances, OLLILA, David W, SARTOR, Carolyn I, GRAHAM, Mark L, PEROU, Charles M

“…Purpose: Gene expression analysis identifies several breast cancer subtypes. We examined the relationship of neoadjuvant chemotherapy response to outcome among…”
Get full text

The Proteasome as a Target for Cancer Therapy by VOORHEES, Peter M, DEES, E. Claire, O'NEIL, Bert, ORLOWSKI, Robert Z

“…The proteasome is a multicatalytic proteinase complex responsible for the degradation of most intracellular proteins, including proteins crucial to cell cycle…”
Get full text

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group by Harvey, R Donald, Mileham, Kathryn F, Bhatnagar, Vishal, Brewer, Jamie R, Rahman, Atiqur, Moravek, Cassadie, Kennedy, Andrew S, Ness, Elizabeth A, Dees, E Claire, Ivy, S Percy, Ebbinghaus, Scot W, Schenkel, Caroline, Uldrick, Thomas S

“…Washout periods and concomitant medication exclusions are common in cancer clinical trial protocols. These exclusion criteria are often applied inconsistently…”
Get full text

CYP2C83 increases risk of neuropathy in breast cancer patients treated with paclitaxel by Hertz, D.L., Roy, S., Motsinger-Reif, A.A., Drobish, A., Clark, L.S., McLeod, H.L., Carey, L.A., Dees, E.C.

“…Paclitaxel-induced neuropathy is an adverse event that often leads to therapeutic disruption and patient discomfort. We attempted to replicate a previously…”
Get full text

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations by DEES, E. Claire, COHEN, Roger B, MEHREN, Margaret Von, STINCHCOMBE, Thomas E, HUA LIU, VENKATAKRISHNAN, Karthik, MANFREDI, Mark, FINGERT, Howard, BURRIS, Howard A, INFANTE, Jeffrey R

“…This phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of the investigational oral drug MLN8237 (alisertib), a…”
Get full text

Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx by Wagner, Lynne I, Gray, Robert J, Sparano, Joseph A, Whelan, Timothy J, Garcia, Sofia F, Yanez, Betina, Tevaarwerk, Amye J, Carlos, Ruth C, Albain, Kathy S, Olson, Jr, John A, Goetz, Matthew P, Pritchard, Kathleen I, Hayes, Daniel F, Geyer, Charles E, Dees, E Claire, McCaskill-Stevens, Worta J, Minasian, Lori M, Sledge, Jr, George W, Cella, David

“…Cancer-related cognitive impairment (CRCI) is common during adjuvant chemotherapy and may persist. TAILORx provided a novel opportunity to prospectively assess…”
Get full text

Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study by Layman, Rachel M, Han, Hyo S, Rugo, Hope S, Stringer-Reasor, Erica M, Specht, Jennifer M, Dees, E Claire, Kabos, Peter, Suzuki, Samuel, Mutka, Sarah C, Sullivan, Brian F, Gorbatchevsky, Igor, Wesolowski, Robert

“…The PI3K–mTOR pathway is frequently dysregulated in breast cancer. Combining an inhibitor targeting all class I PI3K isoforms and mTOR complex 1 (mTORC1)–mTOR…”
Get full text

First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies by Munster, Pamela, Aggarwal, Rahul, Hong, David, Schellens, Jan H M, van der Noll, Ruud, Specht, Jennifer, Witteveen, Petronella O, Werner, Theresa L, Dees, E Claire, Bergsland, Emily, Agarwal, Neeraj, Kleha, Joseph F, Durante, Michael, Adams, Laurel, Smith, Deborah A, Lampkin, Thomas A, Morris, Shannon R, Kurzrock, Razelle

“…GSK2126458 (GSK458) is a potent inhibitor of PI3K (α, β, γ, and δ), with preclinical studies demonstrating broad antitumor activity. We performed a…”
Get full text

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas by Burris, 3rd, Howard A, Hurwitz, Herbert I, Dees, E Claire, Dowlati, Afshin, Blackwell, Kimberly L, O'Neil, Bert, Marcom, Paul K, Ellis, Matthew J, Overmoyer, Beth, Jones, Suzanne F, Harris, Jennifer L, Smith, Deborah A, Koch, Kevin M, Stead, Andrew, Mangum, Steve, Spector, Neil L

“…This study (EGF10004) assessed the safety/tolerability, pharmacokinetics, and clinical activity of daily oral dosing with lapatinib (GW572016) in patients with…”
Get full text

CYP2C83 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel by Hertz, Daniel L., Motsinger-Reif, Alison A., Drobish, Amy, Winham, Stacey J., McLeod, Howard L., Carey, Lisa A., Dees, E. Claire

“…Paclitaxel is one of the most frequently used chemotherapeutic agents for the treatment of breast cancer patients. Using a candidate gene approach, we…”
Get full text

Risk Perceptions and Psychosocial Outcomes of Women With Ductal Carcinoma In Situ: Longitudinal Results From a Cohort Study by Partridge, Ann, Adloff, Kristie, Blood, Emily, Dees, E. Claire, Kaelin, Carolyn, Golshan, Mehra, Ligibel, Jennifer, de Moor, Janet S., Weeks, Jane, Emmons, Karen, Winer, Eric

“…Background Ductal carcinoma in situ (DCIS) has a generally favorable overall prognosis, with a systemic recurrence rate of approximately 1%, a local recurrence…”
Get full text

Risk factors in child maltreatment: A meta-analytic review of the literature by Stith, Sandra M, Liu, Ting, Davies, L. Christopher, Boykin, Esther L, Alder, Meagan C, Harris, Jennifer M, Som, Anurag, McPherson, Mary, Dees, J.E.M.E.G

“…Abstract This review presents the results of a series of meta-analyses identifying the relative strength of various risk factors for child physical abuse and…”
Get full text

Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study by IRVIN, William J, WALKO, Christine M, RAAB, Rachel E, CORSO, Steven W, PEPPERCORN, Jeffrey M, ANDERSON, Steven M, FRIEDMAN, Kenneth J, OGBURN, Evan T, DESTA, Zeruesenay, FLOCKHART, David A, MCLEOD, Howard L, EVANS, James P, WECK, Karen E, CAREY, Lisa A, IBRAHIM, Joseph G, CHIU, WingK, DEES, E. Claire, MOORE, Susan G, OLAJIDE, Oludamilola A, GRAHAM, Mark L, CANALE, Sean T

“…We examined the feasibility of using CYP2D6 genotyping to determine optimal tamoxifen dose and investigated whether the key active tamoxifen metabolite,…”
Get full text